Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals Limited has announced an extraordinary general meeting scheduled for September 23, 2025, at their Melbourne office. Shareholders are encouraged to participate by submitting proxy forms and questions in advance. This meeting is crucial for discussing company strategies and engaging with shareholders, reflecting Paradigm’s commitment to transparency and stakeholder involvement.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for inflammatory diseases. The company is known for its innovative approach in addressing unmet medical needs, particularly in the area of osteoarthritis and other musculoskeletal disorders.
Average Trading Volume: 800,763
Technical Sentiment Signal: Sell
Current Market Cap: A$119.2M
See more data about PAR stock on TipRanks’ Stock Analysis page.